Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926763 | 0.93 | DPP4 (0.36) | KDREPHB4FGFR1MAPK14CCNA2 | |
| SCHEMBL3927419 | 0.92 | KDR (0.33) | KDREPHB4FGFR1MAPK14CCNA2 | |
| SCHEMBL3933169 | 0.90 | MAPK14 (0.36) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL3927416 | 0.90 | MAPK14 (0.36) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL14395970 | 0.90 | KDR (0.32) | KDREPHB4FGFR1MAPK14CCNA2 | |
| SCHEMBL14396485 | 0.85 | EPHB4 (0.40) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5914429 | 0.82 | EPHB4 (0.42) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL3924760 | 0.81 | HRH4 (0.43) | KDREPHB4FGFR1CCNA2CDK2 | |
| SCHEMBL4004025 | 0.80 | DPP4 (0.36) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5317833 | 0.79 | KDR (0.40) | KDREPHB4FGFR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | claimed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | KDR 299/4885EPHB4 2072/4885FGFR1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.